the injection slows down your progress

In 97% of patients in clinical trials, there was “no development of brain damage.”

The NHS is one of the first health systems in the world to offer this new injection.

A pioneering drug called ocrelizumab, produced by biopharmaceutical company Rochehas managed to create a rapid injection for the treatment of multiple sclerosis, which slows the progression of the disease and reduces hospital treatment time by 90%. A pharmacological milestone for patients living with this disease, which already affects more than 50,000 people in Spain alone. However, for now it has only been approved by the UK.

Thousands of people with multiple sclerosis in this country are to receive a new rapid injection to treat multiple sclerosis. Until now, patients had to receive a double dose intravenously a year, in sessions that could last more than four hours.

The incidence of the disease has gradually increased over the past decades. especially in womenwith a diagnosis of 3 out of 4 patients.

New injection delivered intradermally in just ten minutes and has been tested for over 9000 patients and approved by the UK Healthcare Products Regulatory Agency.

The first symptoms usually begin in people around 25-30 years of age. 5% of patients with multiple sclerosis seek medical attention before the age of 18.

High efficiency

Ocrelizumab showed “greater efficiency» in reducing the symptoms of multiple sclerosis by targeting a specific type of immune cell and 97% of patients completed clinical trials they didn’t experience it”traumatic brain injuries do not develop“after 48 weeks,” the NHS explains in a statement.

Medical Director of the National Health Service Professor Stephen PoveyHe assured that this new injection will allow patients to “spend less time on treatment, while at the same time helping health workers gain time to be able to treat more people and increase hospital capacity.”

Likewise, Powis stressed,great progress“what is the drug that for the first time manages to “change the course of the disease” and claims that, because it is a “more innovative and faster” alternative, it will help improve quality of life of patients“.

Multiple sclerosis is a chronic disease that affects more than 150,000 people (mostly women) worldwide. Great Britain, with 135 new diagnoses per week and can cause brain and spinal cord damage, as well as impaired vision and mobility, among other things.

The National Health Service (NHS) is one of the leading health systems in the world. to offer this new injection, and a new batch is expected to go on sale in the coming weeks.

Multiple sclerosis

Estimated Spanish Society of Neurologyand according to the most recent studies, more than 1,900 new cases of multiple sclerosis are registered each year in Spain, as this disease already registers an incidence of 4.2 new cases per year per 100,000 inhabitants. Thus, Spain is a country with medium to high prevalence and incidence of this disease.

Although we must not forget that multiple sclerosis It remains a serious disease, with the earliest diagnosis currently estimated at one to two years from the onset of symptoms, and greater efficacy and convenience of treatment have led to an improvement in the evolution of the disease, according to research recently presented at the SEN annual meeting. The Impact of Multiple Sclerosis on Social Health (EM) in Spain: Changes in patient perception over the last decade, conducted on 500 patients in more than 60 Spanish hospitals, which showed an improvement in general health, a decrease in disability and need for care, and greater work capacity over the last decade among socio-demographically matched patients with multiple sclerosis.

According to the study, 52.5% of respondents consider their health to be good or very good, compared to 33% of people who said this 10 years ago. More than 60% believe that their quality of life depends largely on medication or medical care and that their quality of life has improved thanks to the care they have received, compared to 40% ten years ago. But perhaps more importantly, almost 82% of respondents remain independently mobile (compared to the previous 27.5%), and that only 11% require support (48.5%), with 7% requiring a wheelchair (23%). In addition, more than 48% of patients surveyed are actively employed, compared to 26.5% in the previous study.